[Long-term study on a new beta2-sympathicomimetic agent and a combination of an oral theophylline-ethylenediamine with retard effect and hexoprenaline (author's transl)].
The effects of a treatment with a new beta2-adrenergic agent (hexoprenaline, Etoscol) as well as a combined therapy of theophylline (Euphylin retard) with the Etoscol on the total resistance were studied on two groups of patients. The therapy resulted in a significant decrease of the total resistance and the combined therapy showed an additional decrease of the resistance values.
D000328:Adult; D000403:Airway Resistance / Q000187:drug effects; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D005260:Female; D006594:Hexoprenaline / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010627:Phenethylamines / Q000627:therapeutic use*; D011674:Pulse / Q000187:drug effects; D013806:Theophylline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors
D003692:Delayed-Action Preparations; D010627:Phenethylamines; D013806:Theophylline; D006594:Hexoprenaline
Langzeituntersuchung mit einem neuen beta-2-Sympathikomimetikum (Hexoprenalin) und einer Kombination (orales Theophyllin-äthylendiamin-Präparat mit Retardwirkung + Hexoprenalin).